Exelixis, Inc. (EXEL)
69.00
-0.84
(-1.20%)
USD |
NASDAQ |
Nov 13, 10:06
Exelixis Net Income (Quarterly) : 218.10M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 218.10M |
| June 30, 2026 | 212.05M |
| March 31, 2026 | 210.47M |
| December 31, 2025 | 244.53M |
| September 30, 2025 | 193.58M |
| June 30, 2025 | 184.85M |
| March 31, 2025 | 159.62M |
| December 31, 2024 | 139.86M |
| September 30, 2024 | 117.97M |
| June 30, 2024 | 226.12M |
| March 31, 2024 | 37.32M |
| December 31, 2023 | 85.52M |
| September 30, 2023 | 1.041M |
| June 30, 2023 | 81.18M |
| March 31, 2023 | 40.03M |
| December 31, 2022 | -30.17M |
| September 30, 2022 | 73.21M |
| June 30, 2022 | 70.67M |
| March 31, 2022 | 68.57M |
| December 31, 2021 | 95.17M |
| September 30, 2021 | 38.20M |
| June 30, 2021 | 96.09M |
| March 31, 2021 | 1.601M |
| December 31, 2020 | 28.39M |
| September 30, 2020 | -32.04M |
| Date | Value |
|---|---|
| June 30, 2020 | 66.82M |
| March 31, 2020 | 48.61M |
| December 31, 2019 | 68.74M |
| September 30, 2019 | 97.45M |
| June 30, 2019 | 79.04M |
| March 31, 2019 | 75.78M |
| December 31, 2018 | 360.09M |
| September 30, 2018 | 126.63M |
| June 30, 2018 | 87.49M |
| March 31, 2018 | 115.86M |
| December 31, 2017 | 38.49M |
| September 30, 2017 | 81.16M |
| June 30, 2017 | 17.60M |
| March 31, 2017 | 16.64M |
| December 31, 2016 | 35.12M |
| September 30, 2016 | -11.28M |
| June 30, 2016 | -34.84M |
| March 31, 2016 | -59.22M |
| December 31, 2015 | -41.57M |
| September 30, 2015 | -47.56M |
| June 30, 2015 | -43.36M |
| March 31, 2015 | -35.17M |
| December 31, 2014 | -57.95M |
| September 30, 2014 | -62.56M |
| June 30, 2014 | -73.41M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | -122.83M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Cytokinetics, Inc. | -190.07M |
| Gilead Sciences, Inc. | 2.429B |
| Ionis Pharmaceuticals, Inc. | -109.97M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 658.70M |
| Total Expenses (Quarterly) | 440.60M |
| EPS Diluted (Quarterly) | 0.8528 |
| Enterprise Value | 16.36B |
| Gross Profit Margin (Quarterly) | 96.02% |
| Profit Margin (Quarterly) | 33.11% |
| Earnings Yield | 4.84% |
| Operating Earnings Yield | 5.50% |
| Normalized Earnings Yield | 4.845 |